APAC Cancer Pain Management Market Analysis Report [2022-30]

APAC Cancer Pain Management Market Analysis

$ 3999

The APAC Cancer Pain Management market is projected to grow from $1.37 Bn in 2022 to $ 2.28 Mn by 2030, registering a CAGR of 6.57% during the forecast period of 2022-2030. The main factors driving the growth would be rising cancer incidence, advancements in pain management technologies, government support, and growing healthcare infrastructure. The market is segmented by drug type and by disease. Some of the major players include Accord Healthcare, Aoxing Pharmaceutical, Hisamitsu Pharmaceutical, Mundipharma, Pfizer, Abbott, and Teva Pharmaceuticals.

ID: IN10APHS002 CATEGORY: Healthcare Services GEOGRAPHY: Asia - Pacific AUTHOR: Neha Davda

Buy Now

APAC Cancer Pain Management Market Executive Summary

The APAC Cancer Pain Management market is projected to grow from $1.37 Bn in 2022 to $ 2.28 Mn by 2030, registering a CAGR of 6.57% during the forecast period of 2022 - 2030. In 2017, the WHO Western Pacific Area, which includes several countries in the Asia-Pacific area, had a total health spending as a percentage of GDP of 7.2%. But within the region, this ratio might vary greatly from one country to the next.

Cancer itself or its related therapies, such as chemotherapy and surgery, can both induce pain. What medications are used and how they are administered depends on the kind, location, and intensity of the pain. To treat cancer pain, a wide variety of medications are employed. Acetaminophen and NSAIDs, which are non-opioids, are more routinely used to treat mild to moderate cancer pain than strong opioids, for example, are to treat severe pain.

On the strength of improved patient care services and significant government, investments in nations like India, Brazil, and China, the Asia Pacific region is expected to become known for cancer pain management.

APAC cancer pain management market analysis

Market Dynamics

Market Growth Drivers

The market for cancer pain management in the Asia Pacific region is anticipated to increase significantly over the next few years, driven by factors such as rising cancer incidence, advancements in pain management technologies, and growing healthcare infrastructure. Moreover, governments in the Asia-Pacific region are making investments in their healthcare infrastructure and supporting programs targeted at enhancing access to cancer pain management services. For instance, the Indian government has started a number of programs to help patients there has better access to cancer treatments and pain management services.

Market Restraints

The cost of cancer pain management services is high in many Asia Pacific nations, which may restrain market expansion. This is partly because cancer treatments, painkillers, and other medical procedures are so expensive. Additionally, painkillers include side effects such as nausea, vertigo, urine incontinence, trouble sleeping, and constipation, which can limit their usage and have an effect on the development of the market for cancer pain management in the region.

Competitive Landscape

Key Players

Accord Healthcare
Aoxing Pharmaceutical
Hisamitsu Pharmaceutical
Mundipharma
Pfizer
Abbott
Teva Pharmaceuticals

Notable Recent Deals

January 2020: Mundipharma and Samsung Bioepis have entered into a partnership to promote Samsung Bioepis' initial batch of biosimilar candidates in Taiwan and Hong Kong. The agreement covers all of Samsung Bioepis' potential biosimilar cancer and immune system treatments, including SB3 (trastuzumab), SB4 (etanercept), SB5 (adalimumab), and SB8 (bevacizumab).

Healthcare Policies and Regulatory Landscape

The regulatory environment and healthcare regulations for the Asia Pacific cancer pain management market differ by nation. In order to enhance access to medical treatments, particularly cancer pain management, many governments in the Asia Pacific area are investing in their healthcare industries. For instance, the government in Japan offers comprehensive insurance coverage for those with cancer, which covers therapies for pain management. Similar to the US, Australia has a publicly funded healthcare system that allows the government to pay for cancer treatments and pain management services.

In the Asia Pacific area, there are various regulatory frameworks for the treatment of cancer pain, with some nations having well-established rules and others having less onerous ones. For instance, the Central Drugs Standard Control Organization (CDSCO) in India governs the approval and usage of pain management drugs, whereas the TGA in Australia oversees the same matters.

Reimbursement Scenario

The Asia Pacific area has different reimbursement practices for treating cancer pain from country to country. The general method of reimbursement for cancer pain management services is a combination of public and private insurance, with the details of payment varying by nation and insurance company. Cancer pain treatment services are covered by public insurance in many Asia-Pacific nations. For instance, the national health insurance program in Japan provides coverage for a variety of pain management services, including those for people with cancer. Cancer treatments and pain management services are covered by Australia's publicly funded healthcare system.

In the Asia Pacific area, private insurance plays a significant role in funding cancer pain treatment therapies. For instance, a large number of patients in China depend on private insurance to pay for cancer treatments and pain management services. Private insurance companies in India give coverage for cancer pain relief, though the breadth of such coverage varies from company to company.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.